You are here

AusPAR: Crizanlizumab

Australian Public Assessment Report

24 August 2021
AusPAR Details
AusPAR
Active Ingredient
Crizanlizumab
Product Name
Adakveo
Sponsor
Novartis Pharmaceuticals Australia Pty Ltd
Submission Number
PM-2019-05705-1-6
Submission Type
New biological entity
Decision
Approved
AusPAR Date
16 July 2021
Publication Date

24 August 2021